These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. A viral-fusion-peptide-like molecular switch drives membrane insertion of botulinum neurotoxin A1. Lam KH; Guo Z; Krez N; Matsui T; Perry K; Weisemann J; Rummel A; Bowen ME; Jin R Nat Commun; 2018 Dec; 9(1):5367. PubMed ID: 30560862 [TBL] [Abstract][Full Text] [Related]
10. Comparison of the catalytic properties of the botulinum neurotoxin subtypes A1 and A5. Wang D; Krilich J; Pellett S; Baudys J; Tepp WH; Barr JR; Johnson EA; Kalb SR Biochim Biophys Acta; 2013 Dec; 1834(12):2722-8. PubMed ID: 24096023 [TBL] [Abstract][Full Text] [Related]
11. Botulinum Neurotoxin A4 Has a 1000-Fold Reduced Potency Due to Three Single Amino Acid Alterations in the Protein Receptor Binding Domain. Tepp WH; Bradshaw M; Gardner AP; Kaufman RL; Barbieri JT; Pellett S Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982762 [TBL] [Abstract][Full Text] [Related]
12. High resolution crystal structures of Clostridium botulinum neurotoxin A3 and A4 binding domains. Davies JR; Rees J; Liu SM; Acharya KR J Struct Biol; 2018 May; 202(2):113-117. PubMed ID: 29288126 [TBL] [Abstract][Full Text] [Related]
13. Entry of Botulinum Neurotoxin Subtypes A1 and A2 into Neurons. Kroken AR; Blum FC; Zuverink M; Barbieri JT Infect Immun; 2017 Jan; 85(1):. PubMed ID: 27795365 [TBL] [Abstract][Full Text] [Related]
14. Enhancing toxin-based vaccines against botulism. Przedpelski A; Tepp WH; Zuverink M; Johnson EA; Pellet S; Barbieri JT Vaccine; 2018 Feb; 36(6):827-832. PubMed ID: 29307477 [TBL] [Abstract][Full Text] [Related]
15. Exchanging the minimal cell binding fragments of tetanus neurotoxin in botulinum neurotoxin A and B impacts their toxicity at the neuromuscular junction and central neurons. Höltje M; Schulze S; Strotmeier J; Mahrhold S; Richter K; Binz T; Bigalke H; Ahnert-Hilger G; Rummel A Toxicon; 2013 Dec; 75():108-21. PubMed ID: 23817019 [TBL] [Abstract][Full Text] [Related]
16. Crystal structure of botulinum neurotoxin subtype A3 cell binding domain in complex with GD1a co-receptor ganglioside. Gregory KS; Liu SM; Acharya KR FEBS Open Bio; 2020 Mar; 10(3):298-305. PubMed ID: 31945264 [TBL] [Abstract][Full Text] [Related]
17. Light chain separated from the rest of the type a botulinum neurotoxin molecule is the most catalytically active form. Gul N; Smith LA; Ahmed SA PLoS One; 2010 Sep; 5(9):e12872. PubMed ID: 20877571 [TBL] [Abstract][Full Text] [Related]
18. Plasma membrane localization signals in the light chain of botulinum neurotoxin. Fernández-Salas E; Steward LE; Ho H; Garay PE; Sun SW; Gilmore MA; Ordas JV; Wang J; Francis J; Aoki KR Proc Natl Acad Sci U S A; 2004 Mar; 101(9):3208-13. PubMed ID: 14982988 [TBL] [Abstract][Full Text] [Related]
19. Recombinant derivatives of botulinum neurotoxin A engineered for trafficking studies and neuronal delivery. Band PA; Blais S; Neubert TA; Cardozo TJ; Ichtchenko K Protein Expr Purif; 2010 May; 71(1):62-73. PubMed ID: 20045734 [TBL] [Abstract][Full Text] [Related]
20. Substrate cleavage and duration of action of botulinum neurotoxin type FA ("H, HA"). Pellett S; Tepp WH; Lin G; Johnson EA Toxicon; 2018 Jun; 147():38-46. PubMed ID: 29273248 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]